Weltruza Patent Expiration

Weltruza is a drug owned by Teva Neuroscience Inc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 10, 2044. Details of Weltruza's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12220418 Olanzapine Compositions And Methods Of Use
Jan, 2044

(17 years from now)

Active
US11813359 Sustained Release Olanzapine Formulations
Oct, 2038

(11 years from now)

Active
US10646443 Sustained Release Olanzapine Formulations
Mar, 2038

(11 years from now)

Active
US9023897 Biodegradable drug delivery compositions
Apr, 2033

(6 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Weltruza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Weltruza's family patents as well as insights into ongoing legal events on those patents.

Weltruza's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Weltruza:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Treatment of Tinnitus With Olanzapine University of Sao Paulo NA COMPLETED
(Sep 1, 2026)
PHASE1
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Alkermes, Inc. NA ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Alkermes, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial Roswell Park Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE2
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer University of Illinois at Chicago NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia University of Arizona NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer OHSU Knight Cancer Institute NA RECRUITING
(Jul 1, 2026)
PHASE2
A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors Kantonsspital Winterthur KSW NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy Blokhin's Russian Cancer Research Center NA RECRUITING
(Jun 1, 2026)
PHASE3
Intranasal Insulin and Olanzapine Study in Healthy Volunteers Centre for Addiction and Mental Health NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery Yale University NA COMPLETED
(May 1, 2026)
PHASE2
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting Affiliated Hospital of Qinghai University NA RECRUITING
(Apr 1, 2026)
PHASE3




Generic Launch

Generic Release Date:

Weltruza's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 10, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Weltruza Generic API suppliers:

Olanzapine is the generic name for the brand Weltruza. 35 different companies have already filed for the generic of Weltruza, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Weltruza's generic

Alternative Brands for Weltruza

There are several other brand drugs in the same treatment category and using the same active ingredient (Olanzapine) as Weltruza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Alkermes Inc
Aristada Used for managing symptoms of schizophrenia through various methods of administration.
Aristada Initio Kit Used for managing symptoms of schizophrenia.
Indivior
Perseris Kit Used for treating schizophrenia.
Intra-cellular
Caplyta Used for treating schizophrenia, bipolar depression, and bipolar disorder by modulating serotonin and dopamine receptor activity.
Janssen Pharms
Invega Trinza used for managing symptoms of schizophrenia in patients who have missed doses or need to restart treatment.
Invega Sustenna used for treating schizophrenia and schizoaffective disorder.
Risperdal Consta Used for maintenance treatment of bipolar I disorder and treatment of schizophrenia.
Otsuka
Abilify Used for treating manic episodes in bipolar disorder, major depressive disorder, irritability in autistic disorder, and maintaining stability in schizophrenia.
Rexulti used for treating major depressive disorder (MDD) and schizophrenia in adults and pediatric patients ages 13 years and older.
Abilify Asimtufii Used for managing symptoms of bipolar I disorder and schizophrenia with extended-release injectable suspension.
Abilify Mycite Kit used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia.
Otsuka Pharm Co Ltd
Abilify Maintena Kit Used for treating bipolar 1 disorder and schizophrenia, including during acute episodes.
Sunovion Pharms Inc
Latuda used for treating bipolar depression, major depressive episodes, and schizophrenia with improvement in attention function, negative symptoms, and cognitive dysfunction.
Teva
Uzedy Used for managing symptoms of schizophrenia.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Olanzapine. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Alkermes Inc
Lybalvi
Cheplapharm
Zyprexa
Zyprexa Relprevv
Zyprexa Zydis
Lilly
Symbyax


Apart from brand drugs containing the same ingredient, some generics have also been filed for Olanzapine, Weltruza's active ingredient. Check the complete list of approved generic manufacturers for Weltruza





About Weltruza

Weltruza is a drug owned by Teva Neuroscience Inc. Weltruza uses Olanzapine as an active ingredient. Weltruza was launched by Teva in 2026.

Approval Date:

Weltruza was approved by FDA for market use on 08 October, 2026.

Active Ingredient:

Weltruza uses Olanzapine as the active ingredient. Check out other Drugs and Companies using Olanzapine ingredient

Dosage:

Weltruza is available in powder form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
531MG/VIAL POWDER Prescription SUBCUTANEOUS
318MG/VIAL POWDER Prescription SUBCUTANEOUS
425MG/VIAL POWDER Prescription SUBCUTANEOUS